Taysha Gene Therapies (NASDAQ: TSHA) reported Q2 EPS of ($0.09), $0.01 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $1.98 million versus the consensus estimate of $1.82 million.

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.